New drug combo targets rare cancer that resists standard treatment
NCT ID NCT06528769
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 29 times
Summary
This study tests whether combining two drugs—ATRA and cemiplimab—can shrink or slow advanced leiomyosarcoma, a rare soft-tissue cancer. About 16 adults whose cancer worsened after standard chemotherapy will receive ATRA pills for 3 days before each cemiplimab infusion, then cemiplimab alone until the disease progresses or side effects become unacceptable. The main goal is to see how many patients respond, with secondary focus on how long the cancer stays controlled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEIOMYOSARCOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ohio State University Comprehensive Cancer Center
RECRUITINGColumbus, Ohio, 43210, United States
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.